JP7804588B2 - カンナビノイド受容体２型（ｃｂ２）調節物質及びその使用 - Google Patents

カンナビノイド受容体２型（ｃｂ２）調節物質及びその使用

Info

Publication number
JP7804588B2
JP7804588B2 JP2022567080A JP2022567080A JP7804588B2 JP 7804588 B2 JP7804588 B2 JP 7804588B2 JP 2022567080 A JP2022567080 A JP 2022567080A JP 2022567080 A JP2022567080 A JP 2022567080A JP 7804588 B2 JP7804588 B2 JP 7804588B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
solvate
acceptable salt
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022567080A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526783A (ja
JP2023526783A5 (https=
Inventor
エルファティフ エルゼイン，
ジウェン リュウ，
Original Assignee
テオン セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テオン セラピューティクス，インク． filed Critical テオン セラピューティクス，インク．
Publication of JP2023526783A publication Critical patent/JP2023526783A/ja
Publication of JP2023526783A5 publication Critical patent/JP2023526783A5/ja
Priority to JP2026002708A priority Critical patent/JP2026063050A/ja
Application granted granted Critical
Publication of JP7804588B2 publication Critical patent/JP7804588B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2022567080A 2020-05-05 2021-05-05 カンナビノイド受容体２型（ｃｂ２）調節物質及びその使用 Active JP7804588B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026002708A JP2026063050A (ja) 2020-05-05 2026-01-09 カンナビノイド受容体２型（ｃｂ２）調節物質及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063020489P 2020-05-05 2020-05-05
US63/020,489 2020-05-05
US202063054096P 2020-07-20 2020-07-20
US63/054,096 2020-07-20
PCT/US2021/030838 WO2021226206A2 (en) 2020-05-05 2021-05-05 Cannabinoid receptor type 2 (cb2) modulators and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026002708A Division JP2026063050A (ja) 2020-05-05 2026-01-09 カンナビノイド受容体２型（ｃｂ２）調節物質及びその使用

Publications (3)

Publication Number Publication Date
JP2023526783A JP2023526783A (ja) 2023-06-23
JP2023526783A5 JP2023526783A5 (https=) 2024-05-15
JP7804588B2 true JP7804588B2 (ja) 2026-01-22

Family

ID=76181225

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022567080A Active JP7804588B2 (ja) 2020-05-05 2021-05-05 カンナビノイド受容体２型（ｃｂ２）調節物質及びその使用
JP2026002708A Pending JP2026063050A (ja) 2020-05-05 2026-01-09 カンナビノイド受容体２型（ｃｂ２）調節物質及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026002708A Pending JP2026063050A (ja) 2020-05-05 2026-01-09 カンナビノイド受容体２型（ｃｂ２）調節物質及びその使用

Country Status (11)

Country Link
US (3) US11564928B1 (https=)
EP (1) EP4146345A2 (https=)
JP (2) JP7804588B2 (https=)
KR (1) KR20230041654A (https=)
CN (1) CN115835909A (https=)
AU (1) AU2021266732A1 (https=)
BR (1) BR112022022335A2 (https=)
CA (1) CA3181538A1 (https=)
IL (1) IL297908A (https=)
MX (1) MX2022013864A (https=)
WO (1) WO2021226206A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230041654A (ko) * 2020-05-05 2023-03-24 테온 테라퓨틱스, 인크. 칸나비노이드 수용체 유형 2 (cb2) 조정제 및 그의 용도
TW202325306A (zh) * 2021-09-02 2023-07-01 美商天恩治療有限公司 改良免疫細胞之生長及功能的方法
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
CN117624134B (zh) * 2024-01-26 2024-05-03 南昌市第一医院 一种靶向降解hdac4的化合物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053543A1 (en) 2000-12-28 2002-07-11 Shionogi & Co., Ltd. Pyridone derivative having affinity for cannabinoid 2-type receptor
JP2005519907A (ja) 2002-01-17 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なヒドロキシナフチリジノンカルボキサミド類
JP2013518907A (ja) 2010-02-08 2013-05-23 アラーガン インコーポレイテッド カンナビノイド−２作動薬として有用なピリダジン誘導体
WO2017068349A1 (en) 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2988739B2 (ja) * 1990-04-16 1999-12-13 協和醗酵工業株式会社 １，８−ナフチリジン−２−オン誘導体
DE4227747A1 (de) 1992-08-21 1994-02-24 Basf Ag Heteroaromatisch kondensierte Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
CN1875021A (zh) 2003-11-04 2006-12-06 默克公司 取代的萘啶酮衍生物
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
ES2393326T3 (es) 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
US8048894B2 (en) 2007-04-18 2011-11-01 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
WO2009053799A1 (en) * 2007-10-24 2009-04-30 Glenmark Pharmaceuticals, S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
GB0800855D0 (en) 2008-01-17 2008-02-27 Syngenta Ltd Herbicidal compounds
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2482849B1 (en) 2009-09-30 2018-06-06 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
WO2013165898A2 (en) 2012-05-01 2013-11-07 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting resolvases
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
WO2016039749A1 (en) 2014-09-11 2016-03-17 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
JP6777638B2 (ja) 2014-09-19 2020-10-28 マッカイ メディカル ファンデーション ザ プレスビュテロス チャーチ イン タイワン マッカイ メモリアル ホスピタル ベンゾ複素環化合物および薬剤
US20180044350A1 (en) 2015-03-10 2018-02-15 Pottayil Govindan Nair Sasikumar Therapeutic cyclic compounds as immunomodulators
BR112017019304A2 (pt) 2015-03-10 2018-05-08 Aurigene Discovery Technologies Limited compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
BR112017019307A2 (pt) 2015-03-10 2018-05-02 Aurigene Discovery Technologies Limited compostos de 1,3,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
KR102894264B1 (ko) 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
EA201791629A1 (ru) 2015-03-10 2018-02-28 Ауриджен Дискавери Текнолоджис Лимитед 1,3,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017079669A1 (en) 2015-11-04 2017-05-11 Incyte Corporation Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3190103A1 (en) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
US9798514B2 (en) 2016-03-09 2017-10-24 Spotify Ab System and method for color beat display in a media content environment
US20190062272A1 (en) 2016-04-13 2019-02-28 Capten Therapeutics Inc. Small molecules for immunogenic treatment of cancer
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2017202275A1 (zh) 2016-05-23 2017-11-30 中国医学科学院药物研究所 溴代苄醚衍生物、及其制法和药物组合物与用途
CA3025391A1 (en) 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060256T2 (hu) 2016-06-20 2023-02-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
EA201990221A1 (ru) 2016-07-08 2019-06-28 Бристол-Маерс Сквибб Компани 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов
JP2019530732A (ja) 2016-08-03 2019-10-24 アライジング・インターナショナル・インコーポレイテッドＡｒｉｓｉｎｇ Ｉｎｔｅｒｎａｔｉｏｎａｌ， Ｉｎｃ． 免疫モジュレータとして有用な対称または半対称化合物
US10563620B2 (en) 2016-08-12 2020-02-18 Rolls-Royce North American Technologies Inc. Expandable exhaust cone
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US10734026B2 (en) 2016-09-01 2020-08-04 Facebook, Inc. Systems and methods for dynamically providing video content based on declarative instructions
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CA3070073A1 (en) 2017-07-18 2019-01-24 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20230041654A (ko) * 2020-05-05 2023-03-24 테온 테라퓨틱스, 인크. 칸나비노이드 수용체 유형 2 (cb2) 조정제 및 그의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053543A1 (en) 2000-12-28 2002-07-11 Shionogi & Co., Ltd. Pyridone derivative having affinity for cannabinoid 2-type receptor
JP2005519907A (ja) 2002-01-17 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なヒドロキシナフチリジノンカルボキサミド類
JP2013518907A (ja) 2010-02-08 2013-05-23 アラーガン インコーポレイテッド カンナビノイド−２作動薬として有用なピリダジン誘導体
WO2017068349A1 (en) 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
ANNA G COOPER; ET AL，DEVELOPMENT OF SELECTIVE, FLUORESCENT CANNABINOID TYPE 2 RECEPTOR LIGANDS BASED ON A 1,8-NAPHTHYRIDIN-2-(1H)-ONE-3-CARBOXAMIDE SCAFFOLD，MEDCHEMCOMM，2018年12月12日，VOL:9, NR:12，PAGE(S):2055 - 2067，https://pubs.rsc.org/en/content/articlepdf/2018/md/c8md00448j
ANNA G COOPER; ET AL，DEVELOPMENT OF SELECTIVE, FLUORESCENT CANNABINOID TYPE 2 RECEPTOR LIGANDS BASED ON A 以下備考，MEDCHEMCOMM，2018年12月12日，VOL:9, NR:12，PAGE(S):2055 - 2067，https://pubs.rsc.org/en/content/articlepdf/2018/md/c8md00448j，1,8-NAPHTHYRIDIN-2-(1H)-ONE-3-CARBOXAMIDE SCAFFOLD
CLEMENTINA MANERA; ET AL，NEW QUINOLONE- AND 1,8-NAPHTHYRIDINE-3-CARBOXAMIDES AS SELECTIVE CB2 RECEPTOR AGONISTS WITH ANTICANCER AND IMMUNO-MODULATORY ACTIVITY，EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY，NL，ELSEVIER，2015年04月24日，VOL:97，PAGE(S):10 - 18，http://dx.doi.org/10.1016/j.ejmech.2015.04.034
CLEMENTINA MANERA; ET AL，NEW QUINOLONE- AND 1,8-NAPHTHYRIDINE-3-CARBOXAMIDES AS SELECTIVE CB2 RECEPTOR AGONISTS 以下備考，EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY，NL，ELSEVIER，2015年04月24日，VOL:97，PAGE(S):10 - 18，http://dx.doi.org/10.1016/j.ejmech.2015.04.034，WITH ANTICANCER AND IMMUNO-MODULATORY ACTIVITY
CLEMENTINA MANERA; ET AL，RATIONAL DESIGN, SYNTHESIS AND ANTI-PROLIFERATIVE PROPERTIES OF NEW CB2 SELECTIVE CANNABINOID RECEPTOR LIGANDS: AN INVESTIGATION OF THE 1,8-NAPHTHYRIDIN-2(1H)-ONE SCAFFOLD，EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY，NL，ELSEVIER，2012年03月15日，VOL:52，PAGE(S):284 - 294，http://dx.doi.org/10.1016/j.ejmech.2012.03.031
CLEMENTINA MANERA; ET AL，RATIONAL DESIGN, SYNTHESIS AND ANTI-PROLIFERATIVE PROPERTIES OF NEW CB2 SELECTIVE 以下備考，EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY，NL，ELSEVIER，2012年03月15日，VOL:52，PAGE(S):284 - 294，http://dx.doi.org/10.1016/j.ejmech.2012.03.031，CANNABINOID RECEPTOR LIGANDS: AN INVESTIGATION OF THE 1,8-NAPHTHYRIDIN-2(1H)-ONE SCAFFOLD
CLEMENTINA MANERA; ET AL，RATIONAL DESIGN, SYNTHESIS, AND PHARMACOLOGICAL PROPERTIES OF NEW 1,8-NAPHTHYRIDIN-2(1H)- 以下備考，JOURNAL OF MEDICINAL CHEMISTRY，2009年06月25日，VOL:52, NR:12，PAGE(S):3644 - 3651，https://pubs.acs.org/doi/pdf/10.1021/jm801563d，ON-3-CARBOXAMIDE DERIVATIVES AS HIGHLY SELECTIVE CANNABINOID-2 RECEPTOR AGONISTS
CLEMENTINA MANERA; ET AL，RATIONAL DESIGN, SYNTHESIS, AND PHARMACOLOGICAL PROPERTIES OF NEW 1,8-NAPHTHYRIDIN-2(1H)-ON-3-CARBOXAMIDE DERIVATIVES AS HIGHLY SELECTIVE CANNABINOID-2 RECEPTOR AGONISTS，JOURNAL OF MEDICINAL CHEMISTRY，2009年06月25日，VOL:52, NR:12，PAGE(S):3644 - 3651，https://pubs.acs.org/doi/pdf/10.1021/jm801563d
ELENA CICHERO; ET AL，COMFA AND COMSIA ANALYSES ON 4-OXO-1,4-DIHYDROQUINOLINE AND 4-OXO-1,4-DIHYDRO-1,5-, -1,6- 以下備考，JOURNAL OF MOLECULAR MODELING，ドイツ，SPRINGER，2009年10月，VOL:16, NR:4，PAGE(S):677 - 691，https://link.springer.com/article/10.1007/s00894-009-0580-4，AND -1,8-NAPHTHYRIDINE DERIVATIVES AS SELECTIVE CB2 RECEPTOR AGONISTS
ELENA CICHERO; ET AL，COMFA AND COMSIA ANALYSES ON 4-OXO-1,4-DIHYDROQUINOLINE AND 4-OXO-1,4-DIHYDRO-1,5-, -1,6-AND -1,8-NAPHTHYRIDINE DERIVATIVES AS SELECTIVE CB2 RECEPTOR AGONISTS，JOURNAL OF MOLECULAR MODELING，ドイツ，SPRINGER，2009年10月，VOL:16, NR:4，PAGE(S):677 - 691，https://link.springer.com/article/10.1007/s00894-009-0580-4
HAYASHI, Hiroaki et al.，"5-HT3 Receptor antagonists. 2. 4-Hydroxy-4-quinolinecarboxylic acid derivatives"，Journal of Medicinal Chemistry，1993年，Vol. 36，No. 5，p. 617-626，DOI: https://pubs.acs.org/doi/abs/10.1021/jm00057a011
JOHNS, Brian A. et al.，"Combining symmetry elements results in potent naphthyridinone (NTD) HIV-1 integrase inhibitors"，Bioorganic & Medicinal Chemistry Letters，2011年，Vol. 21，No. 21，p. 6461-6464，DOI: http://dx.doi.org/10.1016/j.bmcl.2011.08.082
PASQUINI, Serena et al.，"Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 4. Identification of New Potent and Selective Ligands for the Cannabinoid Type 2 Receptor with Diverse Substitution Patterns and Antihyperalgesic Effects in Mice"，Journal of Medicinal Chemistry，2011年，Vol. 54，No. 15，p. 5444-5453，DOI: dx.doi.org/10.1021/jm200476p
REGISTRY（STN）[online]，Entered STN: 04 Nov 2011，[検索日2025.03.21]，CAS登録番号1341014-06-9, 1340947-14-9, 1340928-44-0, 1340920-78-6, 1340792-23-5, 1340774-43-7, 1340727-30-1, 1340722-37-3
REGISTRY（STN）[online]，Entered STN: 04 Nov 2011，2025年03月12日，[検索日2025.03.12]，CAS登録番号1340928-59-7, 1340820-12-3, 1340843-73-3, 1340792-16-6
REGISTRY（STN）[online]，Entered STN: 04 Nov 2011，2025年03月12日，[検索日2025.03.12]，CAS登録番号1340928-59-7, 1340820-12-3, 1340843-73-3,1340792-16-6
VALENTINA LUCCHESI; ET AL，CB2-SELECTIVE CANNABINOID RECEPTOR LIGANDS: SYNTHESIS, PHARMACOLOGICAL EVALUATION, AND MOLECULAR MODELING INVESTIGATION OF 1,8-NAPHTHYRIDIN-2(1H)-ONE-3-CARBOXAMIDES，JOURNAL OF MEDICINAL CHEMISTRY，2014年11月13日，VOL:57, NR:21，PAGE(S):8777 - 8791，https://pubs.acs.org/doi/pdf/10.1021/jm500807e
VALENTINA LUCCHESI; ET AL，CB2-SELECTIVE CANNABINOID RECEPTOR LIGANDS: SYNTHESIS, PHARMACOLOGICAL EVALUATION, 以下備考，JOURNAL OF MEDICINAL CHEMISTRY，2014年11月13日，VOL:57, NR:21，PAGE(S):8777 - 8791，https://pubs.acs.org/doi/pdf/10.1021/jm500807e，AND MOLECULAR MODELING INVESTIGATION OF 1,8-NAPHTHYRIDIN-2(1H)-ONE-3-CARBOXAMIDES

Also Published As

Publication number Publication date
EP4146345A2 (en) 2023-03-15
US20230143502A1 (en) 2023-05-11
JP2026063050A (ja) 2026-04-10
JP2023526783A (ja) 2023-06-23
CA3181538A1 (en) 2021-11-11
CN115835909A (zh) 2023-03-21
AU2021266732A1 (en) 2023-01-05
MX2022013864A (es) 2023-03-09
WO2021226206A3 (en) 2021-12-16
US11564928B1 (en) 2023-01-31
US20240252504A1 (en) 2024-08-01
IL297908A (en) 2023-01-01
WO2021226206A2 (en) 2021-11-11
US11957689B2 (en) 2024-04-16
KR20230041654A (ko) 2023-03-24
BR112022022335A2 (pt) 2023-01-10

Similar Documents

Publication Publication Date Title
JP7804588B2 (ja) カンナビノイド受容体２型（ｃｂ２）調節物質及びその使用
JP7657792B2 (ja) メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
WO2018020474A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
WO2022086920A1 (en) Glutaminyl-peptide cyclotransferase like (qpctl) protein inhibitors and uses thereof
JP6305510B2 (ja) ヤヌスキナーゼ阻害剤としての非環式シアノエチルピラゾロピリドン
WO2023205173A1 (en) Substituted piperidines and substituted tetrahydropyridines as immune-modulating compounds
JP2017531672A (ja) ヤヌスキナーゼ阻害剤としてのエチルＮ−Ｂｏｃピペリジニルピラゾロピリドン類
TW202208350A (zh) 四級吲唑糖皮質素受體拮抗劑
JP2025505230A (ja) 二環式ヘテロアリール化合物およびその使用
EP4153652A1 (en) Monocarboxylic acid transporter 4 (mct4) modulators and uses thereof
EP4673441A1 (en) Lzk inhibitors
EP4683913A1 (en) Substituted thiophene fused derivatives, compositions comprising the same and their use as pharmaceuticals
EP3490995A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
WO2024182551A1 (en) Lzk inhibitors
CA3256816A1 (en) LRRK2 INHIBITORS
JP2026514055A (ja) Ｅｒｂｂ２阻害薬
WO2025188848A1 (en) Lzk inhibitors
KR20260022448A (ko) 디히드로피리미딘-2,4(1h,3h)-디온을 함유하는 폴리시클릭 유도체 및 이의 약학적 조성물, 이의 제조 방법 및 이의 용도
CA3256809A1 (en) LRRK2 INHIBITORS
HK40041073A (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251211

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260109

R150 Certificate of patent or registration of utility model

Ref document number: 7804588

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150